Literature DB >> 23348245

Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature.

Osnat Ashur-Fabian1, Deborah T Blumenthal, Mati Bakon, Dvora Nass, Paul J Davis, Aleck Hercbergs.   

Abstract

Glioblastoma multiforme (GBM) is the most malignant and frequent brain tumor, with an aggressive growth pattern and poor prognosis despite best treatment modalities. Long-term survival of patients with GBM is rare. Optic glioma represents 0.6-1.2% of all brain tumors. Unlike low-grade optic gliomas in children, optic gliomas in adults are highly aggressive and death usually occurs in less than a year. Prolonged progression-free survival and survival rates have been reported in association with induced hypothyroidism in two clinical trials for recurrent GBM. We present the clinical, radiological, and pathological findings in a patient with inoperable GBM of the optic chiasm. Following failure of initial, standard radiation and temozolomide therapy, chemical hypothyroidism was induced using the antithyroid thioamide, propylthiouracil, followed by carboplatin chemotherapy. Initial thyroid stimulating hormone, free T4, and free T3 analysis was carried out and then monthly. This patient responded rapidly to treatment (clinically and with tumor regression within 4 weeks) on two separate occasions with an extended remission period (2.5 years) and prolonged overall survival (4.5 years). We report the successful long-term tumor response to medically induced chemical hypothyroidism in conjunction with carboplatinum chemotherapy of an adult patient with grade IV GBM of the optic chiasm. These clinical observations find mechanistic support from the recent identification of potent mitogenic actions of the thyroid hormone, L-thyroxine, in malignant glioma through binding to a cognate thyroid hormone receptor on the αvβ3 integrin. Approaches to block its activity are now explored in preclinical studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348245     DOI: 10.1097/CAD.0b013e32835c7a47

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  8 in total

Review 1.  Malignant optic glioma - the spectrum of disease in a case series.

Authors:  Ghislaine L Traber; Athina Pangalu; Manuela Neumann; Joao Costa; Michael Weller; Ruth Huna-Baron; Klara Landau
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-26       Impact factor: 3.117

2.  Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study.

Authors:  Aleck Hercbergs; Rebecca E Johnson; Osnat Ashur-Fabian; David H Garfield; Paul J Davis
Journal:  Oncologist       Date:  2014-11-19

Review 3.  The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.

Authors:  Maria V Deligiorgi; Dimitrios T Trafalis
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

Review 4.  Optic Pathway-Hypothalamic Glioma Apoplexy: A Report of Two Cases and Systematic Review of the Literature.

Authors:  Saleh Baeesa; Yazid Maghrabi; Rana Moshref; Jaudah Al-Maghrabi
Journal:  Front Surg       Date:  2022-05-30

5.  Hormones and immunity in cancer: are thyroid hormones endocrine players in the microglia/glioma cross-talk?

Authors:  Cristiana Perrotta; Clara De Palma; Emilio Clementi; Davide Cervia
Journal:  Front Cell Neurosci       Date:  2015-06-23       Impact factor: 5.505

6.  Glioblastoma in the optic chiasm: A case report.

Authors:  Lina F Merchancano-Esquivel; Carlos Felipe Marín-Díaz; Valentina Mejía-Quiñones; Ana María Granados-Sánchez
Journal:  Radiol Case Rep       Date:  2021-12-28

7.  Glioblastoma multiforme of the optic chiasm: A rare case of common pathology.

Authors:  Kirill A Lyapichev; Amade Bregy; Adrienne Cassel; Chelsea Handfield; Jose Velazquez-Vega; Matthew D Kay; Gregory Basil; Ricardo J Komotar
Journal:  Surg Neurol Int       Date:  2016-07-07

8.  Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management.

Authors:  Marwa S Hamza; Shaker A Mousa
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.